Item 2.02.
|
Results of Operations and Financial Condition.
|
On March 12, 2020, Aldeyra Therapeutics, Inc. (the Company) issued a press release and is holding a conference call regarding its financial
results for the year ended December 31, 2019. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
Various statements to be made during the conference call are forward-looking statements under the securities laws, including, but not limited to,
statements regarding the Companys plans and expectations for its product candidates. In some cases, you can identify forward looking statements by terms such as, but not limited to, may, might, will,
objective, intend, should, could, can, would, expect, believe, anticipate, project, target, design,
estimate, predict, potential, aim, plan or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward-looking statements are based
upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties.
The Company is at an early stage of development
and may not ever have any products that generate significant revenue. All of the Companys development timelines may be subject to adjustment depending on recruitment rate, regulatory review, preclinical and clinical results, and other factors
that could delay the initiation or completion of clinical trials. Important factors that could cause actual results to differ materially from those reflected in the Companys forward-looking statements include, among others, the timing of
enrollment, commencement and completion of the Companys clinical trials, the timing and success of preclinical studies and clinical trials conducted by the Company and its development partners; delay in or failure to obtain regulatory approval
of the Companys product candidates; the Companys ability to maintain regulatory approval of the Companys product candidates, and the labeling for any approved products; the risk that prior results, such as signals of safety,
activity or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or trials involving our product candidates; the scope, progress, expansion, and costs of
developing and commercializing the Companys product candidates; uncertainty as to the Companys ability to commercialize (alone or with others) the Companys product candidates following regulatory approval, if any; the size and
growth of the potential markets and pricing for the Companys product candidates and the ability to serve those markets; the Companys expectations regarding the Companys expenses and revenue, the sufficiency or use of the
Companys cash resources and needs for additional financing; political, economic, legal, and social risks that may affect the Companys business or the global economy; the rate and degree of market acceptance of any of the Companys
product candidates; the Companys expectations regarding competition; the Companys anticipated growth strategies; the Companys ability to attract or retain key personnel; the Companys limited sales and marketing
infrastructure; the Companys ability to establish and maintain development partnerships; the Companys ability to successfully integrate acquisitions into our business; the Companys expectations regarding federal, state and foreign
regulatory requirements; regulatory developments in the United States and foreign countries; the Companys ability to obtain and maintain intellectual property protection for the Companys product candidates; the anticipated trends and
challenges in the Companys business and the market in which it operates; and other factors that are described in the Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of
Operations sections of the Companys Annual Report on Form 10-K for the year ended December 31, 2018 and the Companys Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, both of which are on file with
the Securities and Exchange Commission (SEC) and available on the SECs website at www.sec.gov. Additional factors are expected to be described in those sections of the Companys Annual Report on Form 10-K for the year ended
December 31, 2019, expected to be filed with the SEC in the first quarter of 2020.
In addition to the risks described above and in the
Companys other filings with the SEC, other unknown or unpredictable factors also could affect the Companys results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The
information conveyed on the conference call is provided only as of the date of the call, and Aldeyra undertakes no obligation to update any forward-looking statements presented on the call on account of new information, future events, or otherwise,
except as required by law.
The information in Item 2.02 of this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed
filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended (the Securities Act), or the Exchange Act, except as expressly set forth by specific reference in such a filing.